Cargando…

Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China

OBJECTIVE: To assess the potential benefit of chidamide maintenance therapy after induction treatment in peripheral T-cell lymphoma (PTCL). MATERIALS AND METHODS: The clinical data of 48 transplantation-ineligible patients with different PTCL subtypes who received continuous chidamide treatment afte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Wei, Wang, Xingtong, Li, Jia, Yin, Xianying, Zhao, Yangzhi, Tang, Yang, Wang, Anna, Bai, Ou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209709/ https://www.ncbi.nlm.nih.gov/pubmed/35747802 http://dx.doi.org/10.3389/fonc.2022.875469

Ejemplares similares

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

PB1729: RETROSPECTIVE STUDY OF MAINTENANCE THERAPY WITH CHIDAMIDE AFTER TRANSPLANTATION FOR PATIENTS WITH HIGH RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Wang, Xueying, et al.
Publicado: (2023)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
por: Wang, Xing-Tong, et al.
Publicado: (2020)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
por: Wang, Jinni, et al.
Publicado: (2022)

P1201: A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA
por: Wang, Xin, et al.
Publicado: (2023)

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
por: Shafique, Michael R, et al.
Publicado: (2018)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial
por: Xia, Yi, et al.
Publicado: (2023)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma
por: Yan, Fengting, et al.
Publicado: (2017)

The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
por: Jurczak, Wojciech, et al.
Publicado: (2015)

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
por: Pettit, Kristen, et al.
Publicado: (2015)

P1133: CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL
por: Liang, Jinhua, et al.
Publicado: (2023)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis
por: Hur, Joon Young, et al.
Publicado: (2021)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
por: Ridwansyah, Hastono, et al.
Publicado: (2023)

A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy
por: Huang, Zhenghua, et al.
Publicado: (2023)

PB2033: INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Sun, Q., et al.
Publicado: (2022)

Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study
por: Wei, Chong, et al.
Publicado: (2023)

Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
por: Norasetthada, Lalita, et al.
Publicado: (2018)

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
por: Wu, Meng, et al.
Publicado: (2018)

Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin
por: Kadono, Toru, et al.
Publicado: (2022)

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
por: Kang, Junnan, et al.
Publicado: (2021)

Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy
por: Shang, Zhen, et al.
Publicado: (2023)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Wahlin, B. E., et al.
Publicado: (2022)

Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
por: Fuentes, Alejandra C., et al.
Publicado: (2015)

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
por: Chen, Jinghong, et al.
Publicado: (2023)

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
por: Zhang, Wei, et al.
Publicado: (2021)

Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report
por: Hu, Shaoxuan, et al.
Publicado: (2020)

Notification Strategy and Predictors of Outcome in Stroke Ineligible for Reperfusion Therapies
por: Mirolovics, Ágnes, et al.
Publicado: (2019)

Autologous bone marrow cell therapy for peripheral arterial disease
por: Botti, C, et al.
Publicado: (2012)

Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review
por: Jin, Jingxia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_574sv1s9gf74gfq70bcv77i0n4